The impact of age on patient tolerance of mycophenolate following kidney transplantation. Issue 7 (4th May 2020)

• Record Type: Journal Article
• Authors: Rennie, Trijntje J. W.; Petrie, Michaela; Metcalfe, Wendy; Walbaum, David; Joss, Nicola; Barton, Ellen; Marson, Lorna; Clancy, Marc J.; Henderson, Lorna; Traynor, Jamie P.; Geddes, Colin G.; Phelan, Paul J.
• Is Part Of: Nephrology. Volume 25:Issue 7(2020)
• Page Start: 566
• Page End: 574
• Publication Date: 2020-05-04
• Subjects: ageing -- immunosuppression -- kidney transplantation -- mycophenolate -- side effects; Nephrology -- Periodicals; Kidneys -- Diseases -- Periodicals; Nephrologists -- Periodicals; 616.61; 616.61
• DOI: 10.1111/nep.13718
• Languages: English
• ISSNs: 1320-5358

Abstract

Abstract: Background: In Scotland, standard maintenance immunosuppression following kidney transplantation consists of mycophenolate (MPA), tacrolimus and prednisolone irrespective of recipient age. We analyzed the tolerability of this immunosuppression regimen and the association with transplant outcomes. Methods: A national, multicentre retrospective analysis of patients transplanted in 2015 and 2016, comparing graft function, acute rejection, significant infection rates and immunosuppression dosing between patients aged 18 and 59 years (Group 1) and ≥60 years (Group 2). Results: Of the 490 patients, 26% were aged ≥60 years. Acute rejection (AR) rates at 1 year were 15% and 11% in Groups 1 and 2, respectively. Full‐dose MPA was poorly tolerated with 53% in Group 1 and 77% in Group 2 requiring dose reduction or cessation. Female gender and age ≥60 years were independent predictors for MPA dose changes. One year following MPA dose reduction, AR risk was low (5%) in Group 2, however, those remaining on full dose MPA had a 79% increased rate of serious infections. Conclusion: The majority of renal transplant recipients aged ≥60 fail to tolerate full‐dose MPA. In this group, MPA dose reduction is associated with low rejection rates, but full‐dose MPA is associated with high infection rates. We suggest that a tailored approach to immunosuppression in elderly recipients incorporating lower doses of MPA may be appropriate. SUMMARY AT A GLANCE: This national cohort study suggests that full‐dose mycophenolate (MPA) was not well tolerated in older kidney transplant patients, with over 75% of patients =60 years requiring dose reduction or discontinuation. Continuation of full‐dose MPA was associated with a substantially greater risk of infection in the older patients, which was not observed in younger patients.